Ertex Kidney Disease Drug Proves Its Worth In Phase Ii News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.

United statesDavidl ryanGlenn chertowBrian sheltonCarmen bozicGlobal medicines developmentStanford university school of medicineProgram steering committeeBoston globeMedical affairsStanford university schoolErtex kidney disease drug proves its worth in phase ii